Nucala Box / Image: GSK
A January 31st PharmaTimes article says the National Institute for Health Care Excellence has endorsed GlaxoSmithKline’s asthma biologic Nucala for adults with severe refractory eosinophilic asthma. It will be available to adult patients with the rare form of asthma as long as they have a blood eosinophil count of at least 300 cells/microliter, and have had four or more attacks in the past 12 months.
In a study conducted during the regulatory process, Nucala cut the frequency of clinically significant exacerbations by 47% versus the placebo. Nucala is administered via injection every four weeks and costs roughly $1,000 per dose.
Companies in this article
